The Celiac Disease Market is expected to witness significant growth in the coming years, with the market reaching a value of US$ 1,362.1 Million by 2034, showing a growth rate (CAGR) of 9.85% during 2023-2034. The market is being primarily driven by the increasing incidences of inherited chromosomal disorders related to gene mutations, particularly HLA-DQ2 and HLA-DQ8. Additionally, the rising prevalence of risk factors such as gastrointestinal infections, type 1 diabetes, and autoimmune thyroid disease is contributing to the positive outlook for the market.

Enzyme supplements like lactase and alpha-galactosidase are being widely used to improve digestion and reduce symptoms of bloating and gas, further fueling market growth. Key players in the industry are investing heavily in exploring microbial therapies like fecal microbiota transplantation (FMT) and probiotics to alter the gut microbiome and alleviate inflammation in the intestine, which is driving market expansion.

The adoption of gluten-detoxification therapies, aimed at breaking down gluten in the digestive system before triggering an immune response, is gaining popularity and boosting market growth. Additionally, the increasing use of non-invasive methods for diagnosing celiac disease using saliva as an alternative to genetic testing with blood samples is expected to propel market growth in the forecast period.

The report provides a comprehensive analysis of the celiac disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. It covers treatment practices, in-market and pipeline drugs, market performance across major markets, key companies, and their drugs. The United States has the largest patient pool for celiac disease and represents the largest market for treatment. The report also discusses the current treatment practices, market drivers, challenges, and opportunities in the industry.